Harvard Bioscience Competitors

Harvard Bioscience (NASDAQ:HBIO) and Thermo Fisher Scientific (NYSE:TMO) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Insider and Institutional Ownership

64.9% of Harvard Bioscience shares are held by institutional investors. Comparatively, 87.2% of Thermo Fisher Scientific shares are held by institutional investors. 5.4% of Harvard Bioscience shares are held by insiders. Comparatively, 0.4% of Thermo Fisher Scientific shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Harvard Bioscience and Thermo Fisher Scientific's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations for Harvard Bioscience and Thermo Fisher Scientific, as reported by MarketBeat.com.

Harvard Bioscience currently has a consensus target price of $9.00, indicating a potential upside of 29.50%. Thermo Fisher Scientific has a consensus target price of $536.8947, indicating a potential upside of 18.06%. Given Harvard Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Harvard Bioscience is more favorable than Thermo Fisher Scientific.

Risk & Volatility

Harvard Bioscience has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500.

Earnings & Valuation

This table compares Harvard Bioscience and Thermo Fisher Scientific's revenue, earnings per share and valuation.

Thermo Fisher Scientific has higher revenue and earnings than Harvard Bioscience. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Summary

Thermo Fisher Scientific beats Harvard Bioscience on 10 of the 14 factors compared between the two stocks.

Harvard Bioscience (NASDAQ:HBIO) and Illumina (NASDAQ:ILMN) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Insider and Institutional Ownership

64.9% of Harvard Bioscience shares are held by institutional investors. Comparatively, 90.0% of Illumina shares are held by institutional investors. 5.4% of Harvard Bioscience shares are held by insiders. Comparatively, 0.4% of Illumina shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Harvard Bioscience and Illumina's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations for Harvard Bioscience and Illumina, as reported by MarketBeat.com.

Harvard Bioscience currently has a consensus target price of $9.00, indicating a potential upside of 29.50%. Illumina has a consensus target price of $374.50, indicating a potential upside of 0.45%. Given Harvard Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Harvard Bioscience is more favorable than Illumina.

Risk & Volatility

Harvard Bioscience has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500.

Earnings & Valuation

This table compares Harvard Bioscience and Illumina's revenue, earnings per share and valuation.

Illumina has higher revenue and earnings than Harvard Bioscience. Illumina is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Summary

Illumina beats Harvard Bioscience on 10 of the 14 factors compared between the two stocks.

Harvard Bioscience (NASDAQ:HBIO) and Agilent Technologies (NYSE:A) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Insider and Institutional Ownership

64.9% of Harvard Bioscience shares are held by institutional investors. 5.4% of Harvard Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Harvard Bioscience and Agilent Technologies' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations for Harvard Bioscience and Agilent Technologies, as reported by MarketBeat.com.

Harvard Bioscience currently has a consensus target price of $9.00, indicating a potential upside of 29.50%. Agilent Technologies has a consensus target price of $107.4350, indicating a potential downside of 16.48%. Given Harvard Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Harvard Bioscience is more favorable than Agilent Technologies.

Risk & Volatility

Harvard Bioscience has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

Earnings & Valuation

This table compares Harvard Bioscience and Agilent Technologies' revenue, earnings per share and valuation.

Agilent Technologies has higher revenue and earnings than Harvard Bioscience. Agilent Technologies is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Summary

Agilent Technologies beats Harvard Bioscience on 9 of the 14 factors compared between the two stocks.

Harvard Bioscience (NASDAQ:HBIO) and Mettler-Toledo International (NYSE:MTD) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Insider and Institutional Ownership

64.9% of Harvard Bioscience shares are held by institutional investors. Comparatively, 93.2% of Mettler-Toledo International shares are held by institutional investors. 5.4% of Harvard Bioscience shares are held by insiders. Comparatively, 3.2% of Mettler-Toledo International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Harvard Bioscience and Mettler-Toledo International's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations for Harvard Bioscience and Mettler-Toledo International, as reported by MarketBeat.com.

Harvard Bioscience currently has a consensus target price of $9.00, indicating a potential upside of 29.50%. Mettler-Toledo International has a consensus target price of $1,048.3333, indicating a potential downside of 15.56%. Given Harvard Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Harvard Bioscience is more favorable than Mettler-Toledo International.

Risk & Volatility

Harvard Bioscience has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Comparatively, Mettler-Toledo International has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

Earnings & Valuation

This table compares Harvard Bioscience and Mettler-Toledo International's revenue, earnings per share and valuation.

Mettler-Toledo International has higher revenue and earnings than Harvard Bioscience. Mettler-Toledo International is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Summary

Mettler-Toledo International beats Harvard Bioscience on 9 of the 14 factors compared between the two stocks.

Harvard Bioscience (NASDAQ:HBIO) and Waters (NYSE:WAT) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Insider and Institutional Ownership

64.9% of Harvard Bioscience shares are held by institutional investors. Comparatively, 91.8% of Waters shares are held by institutional investors. 5.4% of Harvard Bioscience shares are held by insiders. Comparatively, 1.5% of Waters shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Harvard Bioscience and Waters' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations for Harvard Bioscience and Waters, as reported by MarketBeat.com.

Harvard Bioscience currently has a consensus target price of $9.00, indicating a potential upside of 29.50%. Waters has a consensus target price of $251.25, indicating a potential downside of 17.25%. Given Harvard Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Harvard Bioscience is more favorable than Waters.

Risk & Volatility

Harvard Bioscience has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Comparatively, Waters has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

Earnings & Valuation

This table compares Harvard Bioscience and Waters' revenue, earnings per share and valuation.

Waters has higher revenue and earnings than Harvard Bioscience. Waters is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Summary

Waters beats Harvard Bioscience on 8 of the 14 factors compared between the two stocks.

Bio-Rad Laboratories (NYSE:BIO) and Harvard Bioscience (NASDAQ:HBIO) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Bio-Rad Laboratories and Harvard Bioscience, as reported by MarketBeat.

Bio-Rad Laboratories currently has a consensus target price of $700.00, suggesting a potential upside of 19.89%. Harvard Bioscience has a consensus target price of $9.00, suggesting a potential upside of 29.50%. Given Harvard Bioscience's higher probable upside, analysts clearly believe Harvard Bioscience is more favorable than Bio-Rad Laboratories.

Earnings and Valuation

This table compares Bio-Rad Laboratories and Harvard Bioscience's top-line revenue, earnings per share and valuation.

Bio-Rad Laboratories has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bio-Rad Laboratories and Harvard Bioscience's net margins, return on equity and return on assets.

Insider & Institutional Ownership

63.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 64.9% of Harvard Bioscience shares are owned by institutional investors. 27.5% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 5.4% of Harvard Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Bio-Rad Laboratories has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.73, suggesting that its stock price is 73% more volatile than the S&P 500.

Summary

Bio-Rad Laboratories beats Harvard Bioscience on 8 of the 12 factors compared between the two stocks.